Drug Trial Radar · NCT07441694
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
218
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
May 24, 2030
Study completion May 24, 2030
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Mar 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Conditions
- Myeloproliferative Neoplasms
Interventions
INCA036978Drug
INCA036978 will be administered at protocol defined dose.
Standard disease-directed therapyDrug
A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Dose Limiting Toxicities (DLT)s in Part 1Time frame: Up to 28 days
- Number of participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 2 years
- Number of participants with TEAEs leading to dose modification or discontinuationTime frame: Up to approximately 2 years
Locations
54 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama At Birmingham
Birmingham, Alabama · Not yet recruiting
City of Hope-Lennar Foundation Cancer Center
Irvine, California · Recruiting
Usc Norris Comprehensive Cancer Center
Los Angeles, California · Not yet recruiting
UCLA Medical Hematology & Oncology
Los Angeles, California · Not yet recruiting
Yale Cancer Center
New Haven, Connecticut · Not yet recruiting
University of Miami
Miami, Florida · Not yet recruiting
Moffitt Cancer Center
Tampa, Florida · Not yet recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
John Hopkins Hospital
Baltimore, Maryland · Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Washington University School of Medicine
St Louis, Missouri · Not yet recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Not yet recruiting
Mount Sinai School of Medicine
New York, New York · Not yet recruiting
Weill Cornell Medicine
New York, New York · Not yet recruiting
University of North Carolina At Chapel Hill
Chapel Hill, North Carolina · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Not yet recruiting
Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy
Durham, North Carolina · Not yet recruiting
Cleveland Clinic
Cleveland, Ohio · Not yet recruiting
Ohio State University
Columbus, Ohio · Recruiting
Tristar Bmt/Tcto
Nashville, Tennessee · Recruiting
University of Texas M. D. Anderson Cancer Center
Houston, Texas · Not yet recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Not yet recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Not yet recruiting
Concord General Repatriation Hospital
Concord, New South Wales, Australia · Recruiting
Royal North Shore Hospital
St Leonards, New South Wales, Australia · Recruiting
Icon Cancer Centre
Auchenflower, Queensland, Australia · Recruiting
Epworth Health Care
East Melbourne, Victoria, Australia · Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia · Recruiting
Centre Hospitalier Universitaire (Chu) de Liege
Liège, Belgium · Not yet recruiting
AZ DELTA
Roeselare, Belgium · Not yet recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
McGill University Jewish General Hospital
Montreal, Quebec, Canada · Not yet recruiting
Francois-Xavier
Bordeaux, France · Recruiting
Hospital Saint Louis
Paris, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
University Medical Center Rwth Aachen
Aachen, Germany · Recruiting
Charite Universitaetsmedizin Berlin - Campus Charite Mitte
Berlin, Germany · Recruiting
Universitatklinikum Freiburg
Freiburg im Breisgau, Germany · Recruiting
Universitatsklinikum Halle (Saale)
Halle, Germany · Recruiting
Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
Mainz, Germany · Not yet recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.